The advances in diagnostic data management is staggering. While the number of Apps that record data and share it has steadily increased. However, there is now a stand-out solution that can process inputted data and combine it with the results of a simple lateral flow test while recording the exact GPS position of where the test was taken and delivering the results to those that matter.
The solution is AppDx™ and the technology captures lateral flow rapid test data at point-of-care (POCT), in the community or at home, and provides geo-location and sample IDs for instant access on an online portal.
The benefits of this technology are plain to see: quick and accurate test results, rapid data for analysis and real-time tracking of incidences.
Disease mapping and tracking is in operation, take the Coronavirus disease (COVID-19) Situation Dashboard as an example. But, the portal-data won’t be real-time, i.e. to the minute, and results won’t come from diagnostic devices connected to the portal.
In times of outbreaks, speed is of the essence for containment. Manual disease-location data input adds delays and, in some cases, may require extra personnel, especially where diagnosticians are confined to testing and can’t enter data into a portal immediately.
Using rapid tests and Smartphones addresses the issue of speed as data can be fed into central data-hubs in real-time from any location via automation.
We use a disease outbreak as an example here, as people can appreciate the need for GPS mapping and tracking in an extreme need for containment. However, there are on-going threats such as malaria, HIV and Influenza, where the principles above also apply and could contribute to streamlining diagnosis, allowing faster outcome management and creating real-time datasets for epidemiology.
In 2012, the World Health Organisation urged countries to Test, Treat and Track. The aim was to improve outcome management of malaria patients and document incidences. The initiative deduced that, ‘Improved surveillance…will help determine which areas or population groups are most affected and help target resources to where they are most needed.’
With this in mind, GPS mapping with rapid tests lends itself well to meeting these important surveillance and resourcing needs within WHO’s ‘T3: Test. Treat. Track.’ initiative.
Whether in outbreak or on-going non-outbreak scenarios, the above is applicable. And when considering these points, it becomes immediately obvious why GPS mapping with rapid tests is so important in using data to manage the incidences and spread of diseases.
AppDx™ technology can be customised to read multiple tests and collate data through a common portal to a central data hub. This data could then be accessed by the patients, health professionals and academia for informational, research, treatment and prevention purposes.